ATE230273T1 - Verwendung von deltorphin zur behandlung von zytokin-vermittelter leberschädigung - Google Patents
Verwendung von deltorphin zur behandlung von zytokin-vermittelter leberschädigungInfo
- Publication number
- ATE230273T1 ATE230273T1 AT99921558T AT99921558T ATE230273T1 AT E230273 T1 ATE230273 T1 AT E230273T1 AT 99921558 T AT99921558 T AT 99921558T AT 99921558 T AT99921558 T AT 99921558T AT E230273 T1 ATE230273 T1 AT E230273T1
- Authority
- AT
- Austria
- Prior art keywords
- deltorphin
- seq
- liver damage
- deltorphins
- mediated liver
- Prior art date
Links
- 101800005209 Deltorphin Proteins 0.000 title abstract 2
- BHSURCCZOBVHJJ-NWOHMYAQSA-N Deltorphin A Chemical compound C([C@H](N)C(=O)N[C@H](CCSC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(N)=O)C1=CC=C(O)C=C1 BHSURCCZOBVHJJ-NWOHMYAQSA-N 0.000 title abstract 2
- 206010067125 Liver injury Diseases 0.000 title 1
- 231100000234 hepatic damage Toxicity 0.000 title 1
- 230000008818 liver damage Effects 0.000 title 1
- 102000004127 Cytokines Human genes 0.000 abstract 3
- 108090000695 Cytokines Proteins 0.000 abstract 3
- 231100000753 hepatic injury Toxicity 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 108700040992 Ala(2)- deltorphin I Proteins 0.000 abstract 1
- 108700040991 Ala(2)- deltorphin II Proteins 0.000 abstract 1
- NUNBRHVOPFWRRG-RCEFDBTISA-N Deltorphin B Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(N)=O)C(C)C)NC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 NUNBRHVOPFWRRG-RCEFDBTISA-N 0.000 abstract 1
- CJAORFIPPWIGPG-QXYJMILXSA-N Deltorphin C Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(N)=O)C(C)C)NC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 CJAORFIPPWIGPG-QXYJMILXSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000010172 mouse model Methods 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7125598A | 1998-05-01 | 1998-05-01 | |
| PCT/US1999/009457 WO1999056767A2 (en) | 1998-05-01 | 1999-04-30 | Method for treating cytokine mediated hepatic injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE230273T1 true ATE230273T1 (de) | 2003-01-15 |
Family
ID=22100214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99921558T ATE230273T1 (de) | 1998-05-01 | 1999-04-30 | Verwendung von deltorphin zur behandlung von zytokin-vermittelter leberschädigung |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1073452B1 (de) |
| JP (1) | JP2002513767A (de) |
| AT (1) | ATE230273T1 (de) |
| AU (1) | AU751972B2 (de) |
| BR (1) | BR9909988A (de) |
| CA (1) | CA2326065A1 (de) |
| DE (1) | DE69904712D1 (de) |
| NZ (1) | NZ507775A (de) |
| WO (1) | WO1999056767A2 (de) |
| ZA (1) | ZA200005924B (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6900178B2 (en) * | 2000-09-12 | 2005-05-31 | University Of Kentucky Research Foundation | Protection against ischemia and reperfusion injury |
| US6875742B2 (en) * | 2000-10-10 | 2005-04-05 | Zymogenetics, Inc. | Method for treating cytokine mediated hepatic injury |
| US7811992B2 (en) | 2002-02-06 | 2010-10-12 | Stasys Technologies, Inc. | Anti-infarction molecules |
| US8530515B2 (en) | 2010-08-09 | 2013-09-10 | William Brusilow | Use of methionine sulfoximine to treat acute liver failure and other diseases caused by an inflammatory cytokine response |
-
1999
- 1999-04-30 NZ NZ507775A patent/NZ507775A/xx unknown
- 1999-04-30 JP JP2000546791A patent/JP2002513767A/ja active Pending
- 1999-04-30 DE DE69904712T patent/DE69904712D1/de not_active Expired - Lifetime
- 1999-04-30 EP EP99921558A patent/EP1073452B1/de not_active Expired - Lifetime
- 1999-04-30 WO PCT/US1999/009457 patent/WO1999056767A2/en not_active Ceased
- 1999-04-30 CA CA002326065A patent/CA2326065A1/en not_active Abandoned
- 1999-04-30 AT AT99921558T patent/ATE230273T1/de not_active IP Right Cessation
- 1999-04-30 BR BR9909988-8A patent/BR9909988A/pt not_active Application Discontinuation
- 1999-04-30 AU AU38742/99A patent/AU751972B2/en not_active Ceased
-
2000
- 2000-10-23 ZA ZA200005924A patent/ZA200005924B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR9909988A (pt) | 2000-12-26 |
| EP1073452B1 (de) | 2003-01-02 |
| EP1073452A2 (de) | 2001-02-07 |
| WO1999056767A3 (en) | 2000-03-02 |
| ZA200005924B (en) | 2002-12-23 |
| DE69904712D1 (de) | 2003-02-06 |
| WO1999056767A2 (en) | 1999-11-11 |
| AU3874299A (en) | 1999-11-23 |
| AU751972B2 (en) | 2002-09-05 |
| NZ507775A (en) | 2003-04-29 |
| JP2002513767A (ja) | 2002-05-14 |
| CA2326065A1 (en) | 1999-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69733132D1 (de) | Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen | |
| NO985575L (no) | FremgangsmÕter og preparater anvendelige for inhibering av <alfa>v<beta>5-mediert angiogenese | |
| ATE281840T1 (de) | Behandlung von diarrhoe | |
| DE69636343D1 (de) | Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen | |
| DE69625691D1 (de) | Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten | |
| EP0636025A4 (en) | Compounds useful for treating allergic or inflammatory diseases. | |
| ATE237330T1 (de) | Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung | |
| ATE247974T1 (de) | Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen | |
| ATE342067T1 (de) | Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon | |
| EP0664128A4 (de) | Pharmazeutisches mittel zur hemmung der tumornekrosefaktorproduktion. | |
| PL327181A1 (en) | Benzofurane carboxyamides and sulphonamides | |
| DE50014532D1 (de) | Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz | |
| DE69210654D1 (de) | Verwendung von Tomoxetine zur Behandlung von Funktionsstörungen der niedrigen Harnwege | |
| DE60140960D1 (de) | Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis | |
| ATE172117T1 (de) | Verwendung von trospiumchlorid zur herstellung eines arzneimittels zur behandlung von blasenkrankheiten | |
| ATE359798T1 (de) | Verwendungvon dextransulfat zur behandlung von ibmir | |
| DE69412662D1 (de) | Angiotensin II-Antagonisten zur Behandlung von viralen Erkrankungen | |
| DE69904712D1 (de) | Verwendung von deltorphin zur behandlung von zytokin-vermittelter leberschädigung | |
| ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
| ATE228006T1 (de) | Verwendung von vip zur erstellung eines medikamentes zur behandlung des endotoxischen schocks in säugetieren | |
| DE60015791D1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
| ATE212845T1 (de) | Verwendung von cytochrome - p 450 - inhibitoren zur hemmung des stoffwechsels von stickstoffsubstituierten acridinen | |
| ATE234614T1 (de) | Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren | |
| DE69131253D1 (de) | Zur behandlung von tumoren und hiv-infektionen nützliches pflanzliches protein | |
| ATE297739T1 (de) | Endothelin-antagonisten zur behandlung von herzversagen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |